You just read:

CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium

News provided by

CTI BioPharma Corp.

Dec 01, 2016, 16:01 ET